Distinct differences in gut microbial composition and functional potential from lean to morbidly obese subjects.


Journal

Journal of internal medicine
ISSN: 1365-2796
Titre abrégé: J Intern Med
Pays: England
ID NLM: 8904841

Informations de publication

Date de publication:
12 2020
Historique:
received: 14 02 2020
revised: 20 04 2020
accepted: 14 05 2020
pubmed: 8 7 2020
medline: 23 2 2021
entrez: 8 7 2020
Statut: ppublish

Résumé

The gut microbiome may contribute to the development of obesity. So far, the extent of microbiome variation in people with obesity has not been determined in large cohorts and for a wide range of body mass index (BMI). Here, we aimed to investigate whether the faecal microbial metagenome can explain the variance in several clinical phenotypes associated with morbid obesity. Caucasian subjects were recruited at our hospital. Blood pressure and anthropometric measurements were taken. Dietary intake was determined using questionnaires. Shotgun metagenomic sequencing was performed on faecal samples from 177 subjects. Subjects without obesity (n = 82, BMI 24.7 ± 2.9 kg m Based on the faecal microbiota composition, we were able to separate subjects with and without obesity. In addition, we found strong associations between gut microbial amino acid metabolism and specific microbial species in relation to clinical features of obesity.

Identifiants

pubmed: 32633011
doi: 10.1111/joim.13137
doi:

Substances chimiques

Amino Acids 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

699-710

Informations de copyright

© 2020 The Association for the Publication of the Journal of Internal Medicine.

Références

Ng M, Fleming T, Robinson M et al. Global, regional, and national prevalence of overweight and obesity in children and adults during 1980-2013: A systematic analysis for the Global Burden of Disease Study 2013. Lancet 2014; 384: 766-81.
Schwartz MW, Seeley RJ, Zeltser LM et al. Obesity pathogenesis: an endocrine society scientific statement. Endocr Rev 2017; 38: 267-96.
Meijnikman AS, Gerdes VE, Nieuwdorp M, Herrema H. Evaluating causality of gut microbiota in obesity and diabetes in humans. Endocr Rev 2018; 39: 133-53.
Vrieze A, Van Nood E, Holleman F et al. Transfer of intestinal microbiota from lean donors increases insulin sensitivity in individuals with metabolic syndrome. Gastroenterology 2012; 143: 913-6.e7.
Ley R, Turnbaugh P, Klein S, Gordon J. Microbial ecology: human gut microbes associated with obesity. Nature 2006; 444: 1022-3.
Turnbaugh PJ, Ley RE, Mahowald MA, Magrini V, Mardis ER, Gordon JI. An obesity-associated gut microbiome with increased capacity for energy harvest. Nature 2006; 444: 1027-31.
Liu R, Hong J, Xu X et al. Gut microbiome and serum metabolome alterations in obesity and after weight-loss intervention. Nat Med 2017; 23: 859-68.
Rothschild D, Weissbrod O, Barkan E et al. Environment dominates over host genetics in shaping human gut microbiota. Nature 2018; 555: 210-5.
Franzosa EA, McIver LJ, Rahnavard G et al. Species-level functional profiling of metagenomes and metatranscriptomes. Nat Methods 2018; 15: 962-8.
Truong DT, Franzosa EA, Tickle TL et al. MetaPhlAn2 for enhanced metagenomic taxonomic profiling. Nat Methods 2015; 12: 902-3.
Chen T, Guestrin C.XGBoost: A Scalable Tree Boosting System n.d. doi: https://doi.org/10.1145/2939672.2939785.
Benjamini Y, Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J R Stat Soc Ser B 1995; 57: 289-300.
Zhernakova A, Kurilshikov A, Bonder MJ et al. Population-based metagenomics analysis reveals markers for gut microbiome composition and diversity. Science (80-) 2016; 352: 565-9.
Aron-Wisnewsky J, Prifti E, Belda E et al. Major microbiota dysbiosis in severe obesity: fate after bariatric surgery. Gut 2019; 68: 70-82.
Turnbaugh PJ, Hamady M, Yatsunenko T et al. A core gut microbiome in obese and lean twins. Nature 2009; 457: 480-4.
Turnbaugh PJ, Ridaura VK, Faith JJ, Rey FE, Knight R, Gordon JI. The effect of diet on the human gut microbiome: a metagenomic analysis in humanized gnotobiotic mice. Sci Transl Med 2009; 1: 6ra14.
Jumpertz R, Le DS, Turnbaugh PJ et al. Energy-balance studies reveal associations between gut microbes, caloric load, and nutrient absorption in humans. Am J Clin Nutr 2011; 94: 58-65.
Kootte RS, Levin E, Salojärvi J et al. Improvement of insulin sensitivity after lean donor feces in metabolic syndrome is driven by baseline intestinal microbiota composition. Cell Metab 2017; 26: 611-9.e6.
Pedersen HK, Gudmundsdottir V, Nielsen HB et al. Human gut microbes impact host serum metabolome and insulin sensitivity. Nature 2016; 535: 376-81.
Koh A, Molinaro A, Ståhlman M et al. Microbially produced imidazole propionate impairs insulin signaling through mTORC1. Cell 2018; 175: 947-61.e17.
Fu J, Bonder MJ, Cenit MC et al. The gut microbiome contributes to a substantial proportion of the variation in blood lipids. Circ Res 2015; 117: 817-24.
Thingholm LB, Rühlemann MC, Koch M et al. Obese individuals with and without type 2 diabetes show different gut microbial functional capacity and composition. Cell Host Microbe 2019; 26: 252-64.e10.
Chassaing B, Koren O, Goodrich JK et al. Dietary emulsifiers impact the mouse gut microbiota promoting colitis and metabolic syndrome. Nature 2015; 519: 92-6.
Suez J, Korem T, Zeevi D et al. Artificial sweeteners induce glucose intolerance by altering the gut microbiota. Nature 2014; 514: 181-6.
Lichtman SW, Pisarska K, Berman ER et al. Discrepancy between self-reported and actual caloric intake and exercise in obese subjects. N Engl J Med 1992; 327: 1893-8.
De Groot P, Scheithauer T, Bakker GJ et al. Donor metabolic characteristics drive effects of faecal microbiota transplantation on recipient insulin sensitivity, energy expenditure and intestinal transit time. Gut 2019; 69: 502-12.
Park HA, Lee JS, Kuller LH. Underreporting of dietary intake by body mass index in premenopausal women participating in the Healthy Women Study. Nutr Res Pract 2007; 1: 231.

Auteurs

A S Meijnikman (AS)

From the, Department of Internal and Vascular Medicine, Academic Medical Center, Amsterdam, the Netherlands.
Department of Surgery, Spaarne Hospital, Hoofddorp, the Netherlands.

O Aydin (O)

From the, Department of Internal and Vascular Medicine, Academic Medical Center, Amsterdam, the Netherlands.
Department of Surgery, Spaarne Hospital, Hoofddorp, the Netherlands.

A Prodan (A)

From the, Department of Internal and Vascular Medicine, Academic Medical Center, Amsterdam, the Netherlands.

V Tremaroli (V)

Wallenberg Laboratory, Department of Molecular and Clinical Medicine, Sahlgrenska Academy, Goteborgs Universitet, Gothenburg, Sweden.

H Herrema (H)

From the, Department of Internal and Vascular Medicine, Academic Medical Center, Amsterdam, the Netherlands.

E Levin (E)

From the, Department of Internal and Vascular Medicine, Academic Medical Center, Amsterdam, the Netherlands.

Y Acherman (Y)

Department of Surgery, Spaarne Hospital, Hoofddorp, the Netherlands.

S Bruin (S)

Department of Surgery, Spaarne Hospital, Hoofddorp, the Netherlands.

V E Gerdes (VE)

From the, Department of Internal and Vascular Medicine, Academic Medical Center, Amsterdam, the Netherlands.
Department of Surgery, Spaarne Hospital, Hoofddorp, the Netherlands.

F Backhed (F)

Wallenberg Laboratory, Department of Molecular and Clinical Medicine, Sahlgrenska Academy, Goteborgs Universitet, Gothenburg, Sweden.
Novo Nordisk Foundation Center for Basic Metabolic Research, Section for Metabolic Receptology and Enteroendocrinology, Faculty of Health Sciences, University of Copenhagen, Copenhagen, Denmark.
Department of Clinical Physiology, Region Västtra Götaland, Sahlgrenska University Hospital, Gothenburg, Sweden.

A K Groen (AK)

From the, Department of Internal and Vascular Medicine, Academic Medical Center, Amsterdam, the Netherlands.

M Nieuwdorp (M)

From the, Department of Internal and Vascular Medicine, Academic Medical Center, Amsterdam, the Netherlands.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH